Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Thomas Chen bought 12,757 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $5.49 per share, for a total transaction of $70,035.93. Following the acquisition, the chief executive officer directly owned 13,705 shares of the company’s stock, valued at $75,240.45. The trade was a 1,345.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Neonc Technologies Stock Performance
Neonc Technologies stock opened at $4.68 on Friday. The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $5.95. Neonc Technologies Holdings, Inc. has a 1-year low of $3.01 and a 1-year high of $12.99.
Neonc Technologies (NASDAQ:NTHI – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities analysts recently issued reports on NTHI shares. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, May 26th. Weiss Ratings cut shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 24th. Maxim Group started coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 price objective for the company. Alliance Global Partners started coverage on shares of Neonc Technologies in a research report on Tuesday, May 19th. They set a “buy” rating and a $13.00 price objective for the company. Finally, Wall Street Zen cut shares of Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Neonc Technologies has an average rating of “Hold” and an average price target of $16.00.
Read Our Latest Analysis on Neonc Technologies
About Neonc Technologies
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Featured Articles
- Five stocks we like better than Neonc Technologies
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
